Recon: Philips no longer selling sleep apnea devices in US after FDA consent decree; BMS’ Opdivo posts disappointing post-kidney cancer trial results

• Vaccines save lives and generate profits. Why is investment lagging? (STAT)
• Merck, Johnson & Johnson CEOs agree to testify in Congress on high drug prices, avoiding Bernie Sanders’ subpoena (STAT)
• First-ever RNA editing trial in US gets clearance, pitting ‘exon editing’ technology against vision loss (Endpoints)
• Philips' US sales of sleep apnea devices face years-long halt after FDA deal (Reuters)
• Top 10 most anticipated drug launches of 2024 (Fierce Pharma)
• Pfizer's layoff campaign ramps back up with dozens of SF-area cuts expected next month (Fierce Pharma)

• Which country has the best health care? That’s the wrong question (STAT)
• Exclusive: UK biotech raises $33.1M to test CF drug that could work on top of standard of care (Endpoints)
• UK government to ban disposable vapes to prevent use by children (Reuters)
• Britain's disposable vape ban hits stocks, divides experts (Reuters)
• Zimbabwe launches door-to-door cholera vaccination campaign (Reuters)
• Lilly in talks with Germany over weight-loss drug coverage -Spiegel (Reuters)
• WuXi Biologics plays defense after US bill brands certain Chinese biopharmas as security threats (Fierce Pharma)

• Another step toward new drugs for Parkinson’s (STAT)
• Cognito raises $35 million for Alzheimer’s treatment device, touts benefits compared to drugs (STAT)
• Mid-stage CNS biotech Alto Neuroscience plots $89M IPO (Endpoints)
• Roche ends KRAS deal with Hookipa Pharma, as biotech lays off 30% of staff (Endpoints)
• Ascendis spins out ophthalmology company; Gamida Cell eyes strategic options (Endpoints)
• Sanofi partners with Synthekine in immunology race (Endpoints)
• Bristol Myers' Opdivo fails part two of post-kidney cancer surgery test as competitor Merck touts new survival data (Endpoints)
• Fractyl has the GUTS: Obesity and diabetes biotech charts $99M IPO (Endpoints)
• Sanofi's $1.7B rare disease gambit; CAR-T boxed warning saga; New biotechs on Nasdaq; A seller's market for M&A?; and more (Endpoints)
• Less corporate, more human: How Sanofi is using the Olympics to change public perceptions (Fierce Pharma)

• Eli Lilly overtakes Tesla in market value (STAT)
• Decentralized trials company Science 37 to go private in deal with diagnostics startup eMed (Endpoints)
• What to watch for as Stryker, Boston Scientific and BD post earnings this week (MedTech Dive)
• Absolutions receives FDA breakthrough designation for abdominal wall closure device (MedTech Dive)
• Globus lays off Nuvasive employees after merger (MedTech Dive)
• How Masimo forced Apple to redesign its smartwatches (MedTech Dive)
• Cook Medical sells ear, nose and throat devices to C2Dx (MedTech Dive)

• 23andMe breach targeted Chinese, Jewish populations (STAT)
• Pricey sickle cell treatments raise daunting new challenges for Medicaid programs (STAT)
• From a small town in Wales, a scientific sleuth has shaken Dana-Farber — and elevated the issue of research integrity (STAT)
• Bayer shares fall nearly 6% on court order to pay $2.25 bln in damages (Reuters)
• Outlining the Legal Arguments Against FDA’s Proposed Rule Regulating LDTs (FDA Law Blog)